Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Starpharma: A Buying Opportunity?

June 22nd, 2006

Starpharma: A Buying Opportunity?

Abstract:
Jack Uldrich: Yesterday, shares of Starpharma’s ADR (Advance Deposit Receipts) plummetted 25 percent on no discernible news. I was surprised and disappointed by the drop — especially because I had just bought more shares the other day when the stock (Nasdaq: SPHRY) was trading at $3.50 and I didn’t think it could go any lower.

Source:
NanoNovus

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Starpharma

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026

COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026

Breathing new life into nanotubes for a cooler planet:Researchers at Skoltech discover a simple, single-step heat treatment that nearly doubles the CO2-trapping power of carbon nanotubes January 30th, 2026

New light-based nanotechnology could enable more precise, less harmful cancer treatment: The approach offers a potential alternative to chemotherapy and radiation by using light and heat to target cancer cells. January 30th, 2026

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project